雌激素受体阳性转移性乳腺癌循环肿瘤DNA的杂交捕获基因组分析
该研究对254例雌激素受体阳性乳腺癌女性患者的循环肿瘤DNA(ctDNA)进行杂交捕获基因组分析,检测62个基因。78%样本至少检出1个基因组改变,常见为TP53(38%)、ESR1(31%)和PIK3CA(31%)。14例配对组织样本中,组织检出突变的89%也在ctDNA中检出。ctDNA基因组分析可能为组织检测提供补充或替代方法。
要点
- 78%的ctDNA样本至少检出1个基因组改变,常见TP53(38%)、ESR1(31%)、PIK3CA(31%)。
- 14例配对样本中,组织检出突变的89%也在ctDNA中检出。
- ESR1改变病例中40%存在多个并发ESR1改变,提示多克隆起源。
核心结论
- 鉴定出与复发/转移性乳腺癌管理相关的基因组改变,包括多种ESR1改变。
- ctDNA基因组分析可敏感检出组织中的突变,扩增检出与ctDNA分数相关。
- ctDNA基因组分析可能为雌激素受体阳性转移性乳腺癌患者提供补充或替代组织基因组检测的方法。
研究设计与样本
- 对254例雌激素受体阳性乳腺癌女性患者的ctDNA进行杂交捕获基因组分析,检测62个基因,中位独特覆盖深度7503×。
- 外周血样本由临床医生在2016年5月至2017年3月常规临床诊疗期间提交。
- 将ctDNA中的基因组改变与配对的肿瘤组织样本及乳腺癌组织基因组数据集进行比较。
主要发现
- 78%的样本至少检出1个基因组改变。
- 常见改变基因:TP53(38%)、ESR1(31%)、PIK3CA(31%)。
- 14例患者有配对ctDNA和组织样本,组织检出突变的89%也在ctDNA中检出。
- 观察到多种ESR1改变,包括突变、重排和扩增;40%的ESR1改变病例存在多个并发ESR1改变;两例观察到ESR1复合突变。
- ESR1改变病例中并发改变:PIK3CA(35%)、FGFR1(16%)、ERBB2(8%)、BRCA1/2(5%)、AKT1(4%)。
临床怎么用
- 作者认为,ctDNA基因组分析可能为雌激素受体阳性转移性乳腺癌患者提供补充或替代组织基因组检测的方法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Genomic changes that occur in breast cancer during the course of disease have been informed by sequencing of primary and metastatic tumor tissue. For patients with relapsed and metastatic disease, evolution of the breast cancer genome highlights the importance of using a recent sample for genomic profiling to guide clinical decision-making. Obtaining a metastatic tissue biopsy can be challenging, and analysis of circulating tumor DNA (ctDNA) from blood may provide a minimally invasive alternative. PATIENTS AND METHODS: Hybrid capture-based genomic profiling was carried out on ctDNA from 254 female patients with estrogen receptor-positive breast cancer. Peripheral blood samples were submitted by clinicians in the course of routine clinical care between May 2016 and March 2017. Sequencing of 62 genes was carried out to a median unique coverage depth of 7503×. Genomic alterations (GAs) in ctDNA were evaluated and compared with matched tissue samples and genomic datasets of tissue from breast cancer. RESULTS: At least 1 GA was reported in 78% of samples. Frequently altered genes were TP53 (38%), ESR1 (31%) and PIK3CA (31%). Temporally matched ctDNA and tissue samples were available for 14 patients; 89% of mutations detected in tissue were also detected in ctDNA. Diverse ESR1 GAs including mutation, rearrangement and amplification, were observed. Multiple concurrent ESR1 GAs were observed in 40% of ESR1-altered cases, suggesting polyclonal origin; ESR1 compound mutations were also observed in two cases. ESR1-altered cases harbored co-occurring GAs in PIK3CA (35%), FGFR1 (16%), ERBB2 (8%), BRCA1/2 (5%), and AKT1 (4%). CONCLUSIONS: GAs relevant to relapsed/metastatic breast cancer management were identified, including diverse ESR1 GAs. Genomic profiling of ctDNA demonstrated sensitive detection of mutations found in tissue. Detection of amplifications was associated with ctDNA fraction. Genomic profiling of ctDNA may provide a complementary and possibly alternative approach to tissue-based genomic testing for patients with estrogen receptor-positive metastatic breast cancer.
引用
- Chung JH, Pavlick D, Hartmaier R, et al. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer. Ann Oncol. 2017. PMID: 28945887. doi:10.1093/annonc/mdx490
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。